LekoskopLekoskop
EN All changes
Medicine recalls and shortages › New approvals › 17 Jul 2024
MHRA approval

vibegron

Published on 17 Jul 2024 · source: MHRA — Medicines and Healthcare products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine vibegron (Obgemsa) to treat the symptoms of overactive bladder (OAB) syndrome in adults.…
MHRA announcement ↗ All events: vibegron

What this means

The MHRA has announced the approval of a medicine or a new indication in the UK. Approval does not mean the product is already available on the NHS: NICE appraisal and commissioning may follow.

Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine vibegron (Obgemsa) to treat the symptoms of overactive bladder (OAB) syndrome in adults. Symptoms may include a sudden need to empty the bladder (urgency), urinating more frequently (urinary frequency), and urinary incontinence.

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.